Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Roluperidone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Minerva Neurosciences Secures $200M To Advance Roluperidone
    Minerva Neurosciences Secures $200M To Advance Roluperidone

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3170126/32445/en/Minerva-Neurosciences-Announces-Financing-of-up-to-200-Million-to-Advance-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia-Through-a-Phase-3-Confi.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Minerva Neurosciences Updates Business, Reports Q2 Financial
    Minerva Neurosciences Updates Business, Reports Q2 Financial

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133933/32445/en/Minerva-Neurosciences-Provides-Business-Updates-and-Second-Quarter-Financial-Results.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share
    Minerva's schizophrenia drug rejected by FDA for 2nd time
    Minerva's schizophrenia drug rejected by FDA for 2nd time

    28 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time

    FIERCE BIOTECH
    28 Feb 2024
    Share Share
    Minerva Neurosciences Announces Update on its NDAfor Roluperidone
    Minerva Neurosciences Announces Update on its NDAfor Roluperidone

    10 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    10 May 2023
    Share Share
    Minerva Neurosciences Announces the NDA Filing for Roluperidone
    Minerva Neurosciences Announces the NDA Filing for Roluperidone

    01 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    01 May 2023
    Share Share
    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone
    Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone

    17 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/17/2535492/32445/en/Minerva-Neurosciences-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Drug-Application-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    17 Oct 2022
    Share Share